GlassScriptPhysician profile
Sarah Eckert Lainhart
NPI 1508860925
$7,386.42
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $1,118 · 2021: $1,751 · 2022: $1,843 · 2023: $1,507 · 2024: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,448.91 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,202.65 | 2019-2024 | |
| Amgen INC. | $915.18 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $800.52 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $705.35 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $414.49 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $340.77 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.73 | 2019-2023 | Jardiance |
| Allergan, INC. | $159.13 | 2020-2021 | |
| Eisai INC. | $148.69 | 2020-2021 | |
| Esperion Therapeutics, INC. | $135.96 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.08 | 2020-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $120.14 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $83.82 | 2019-2022 | |
| Exact Sciences Corporation | $81.10 | 2023 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $75.78 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $58.96 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $56.10 | 2020-2021 | |
| Abbott Laboratories | $54.36 | 2022-2023 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $52.97 | 2022 | |
| Novartis Pharmaceuticals Corporation | $44.96 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $38.51 | 2020-2021 | |
| Dexcom, INC. | $34.25 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $23.49 | 2019-2020 | |
| Medtronic Vascular, INC. | $19.21 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.89 | 2022 | |
| Amarin Pharma, INC. | $16.98 | 2021 | |
| Circassia INC. | $14.58 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.17 | 2023 | Quviviq |
| Ibsa Pharma INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lainhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.